GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: placebo tabletDrug: placebo inhalation solution
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 261
- Registration Number
- NCT01687296
- Locations
- π¨π³
GSK Investigational Site, Wuxi, China
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1040
- Registration Number
- NCT01686633
- Locations
- πΊπ¦
GSK Investigational Site, Zaporizhia, Ukraine
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 316
- Registration Number
- NCT01687283
- Locations
- π¨π³
GSK Investigational Site, Wuxi, China
Effects of Two Doses of a Common Cold Treatment on Alertness
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT01686646
- Locations
- π¬π§
Common Cold Centre, Cardiff, Wales, United Kingdom
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
Phase 3
Completed
- Conditions
- Infections, MeningococcalMeningococcal Disease
- Interventions
- Biological: MenACWY-CRM
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 715
- Registration Number
- NCT01682876
- Locations
- πΊπΈ
GSK Investigational Site, West Jordan, Utah, United States
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Phase 3
Completed
- Conditions
- MumpsMeaslesMeasles-Mumps-Rubella VaccineRubella
- Interventions
- Biological: PriorixBiological: M-M-R IIBiological: VarivaxBiological: HavrixBiological: Prevnar 13
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4538
- Registration Number
- NCT01681992
- Locations
- πΉπ
GSK Investigational Site, Pathum Thani, Thailand
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Other: Data interpretation
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01682005
WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01681979
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
Phase 1
Completed
- Conditions
- Respiratory Disorders
- Interventions
- Biological: NTHI vaccine GSK2838502A (formulation 3)Biological: NTHI vaccine GSK2838503A (formulation 4)Biological: NTHI vaccine GSK2838504A (formulation 5)Biological: NTHI vaccine GSK2838505A (formulation 6)Biological: NTHI vaccine GSK2838508A (formulation 7)Biological: NTHI vaccine GSK2838509A (formulation 8)Biological: NTHI vaccine GSK2838500A (formulation 1)Biological: NTHI vaccine GSK2838501A (formulation 2)Drug: Placebo comparator
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 272
- Registration Number
- NCT01678677
- Locations
- π§πͺ
GSK Investigational Site, Wilrijk, Belgium
Investigation of Topical SB705498 on Healthy Volunteers
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT01673529
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath